Targeted therapies for unresectable stage III non-small cell lung cancer

Until recently, the standard treatment in unresectable stage III non-small cell lung cancer was concurrent chemoradiotherapy, but often with dismal outcome. The introduction of consolidation treatment with immune checkpoint inhibitors has shifted the treatment landscape and prognosis of these patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Remon, Jordi, Hendriks, Lizza E. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794453/
https://www.ncbi.nlm.nih.gov/pubmed/35118328
http://dx.doi.org/10.21037/med-21-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794453/
https://www.ncbi.nlm.nih.gov/pubmed/35118328
http://dx.doi.org/10.21037/med-21-8

Ejemplares similares